Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Association of Immune Checkpoint Inhibitor Therapy With Survival in Patients With Cancers With MUC16 Variants.

JAMA network open - 1 Jun 2020

Yu Yunfang, Lin Dagui, Li Anlin, Chen Yongjian, Ou Qiyun, Hu Hai, Yao Herui

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Immunological
Share to CA-125 Antigen
Share to Carcinoma, Non-Small-Cell Lung
Share to Kaplan-Meier Estimate

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Melanoma

Share to Progression-Free Survival

Share to Proportional Hazards Models

Share to Survival Rate

Source

Open in PubMed Open full text

Identifiers

PMID: 32530468
DOI: 10.1001/jamanetworkopen.2020.5837
PMCID: PMC7292997

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Association of Immune Checkpoint Inhibitor Therapy With Survival in Patients With Cancers With MUC16 Variants.PMID 32530468Read ↗

Association of MUC16 Mutation With Response to Immune Checkpoint Inhibitors in Solid Tumors.Semantic proximity Read ↗

Comprehensive characterization of MUC16 mutations in lung adenocarcinoma for immunotherapies and prognosis: An observational study.Semantic proximity Read ↗

Development and validation of a MUC16 mutation-associated immune prognostic model for lung adenocarcinoma.Semantic proximity Read ↗

CD161 Characterizes an Inflamed Subset of Cytotoxic T Lymphocytes Associated with Prolonged Survival in Human Papillomavirus–Driven Oropharyngeal CancerSemantic proximity Read ↗

MUC16 mutations improve patients’ prognosis by enhancing the infiltration and antitumor immunity of cytotoxic T lymphocytes in the endometrial cancer microenvironmentSemantic proximity Read ↗

High mutation load, immune-activated microenvironment, favorable outcome, and better immunotherapeutic efficacy in melanoma patients harboring MUC16/CA125 mutations.Semantic proximity Read ↗

CD161, a promising Immune Checkpoint, correlates with Patient Prognosis: A Pan-cancer AnalysisSemantic proximity Read ↗

The Association of MUC16 Mutation with Tumor Mutation Burden and Its Prognostic Implications in Cutaneous Melanoma.Semantic proximity Read ↗

Expression signature, prognosis value, and immune characteristics of MUC1 identified by pan-cancer analysisSemantic proximity Read ↗

Association of MUC16 Mutation With Tumor Mutation Load and Outcomes in Patients With Gastric Cancer.Semantic proximity Read ↗

MUC4, MUC16, and TTN genes mutation correlated with prognosis, and predicted tumor mutation burden and immunotherapy efficacy in gastric cancer and pan‐cancerSemantic proximity Read ↗

Prognostic Biomarker MUC4 Mutations in Colon Adenocarcinoma Correlating with Tumor MicroenvironmentSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.